指南与共识消化、代谢与肾脏急症儿科与产科急症

中国遗传性血管性水肿诊断与治疗专家共识(2024版)

Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition).
指南 / 共识 · Int Arch Allergy Immunol · 2025-04-10
一句话结论2024版中国遗传性血管性水肿共识更新了诊断流程与分层治疗策略,强调早期诊断以预防致命性喉水肿。

该共识由中国变态反应、耳鼻咽喉、消化、皮肤及急诊医学多学科专家共同制定,针对遗传性血管性水肿(HAE-C1-INH)提供基于证据的诊疗推荐。诊断流程整合临床表现、C1-INH定量/功能检测及补体C4检测,仅在临床高度怀疑但C1-INH水平/功能正常时进行基因测序。治疗按中国现有药物分层:按需治疗使用艾替班特(中国唯一获批的缓激肽B2受体拮抗剂);短期预防使用雄激素或新鲜冰冻血浆应对操作诱因;长期预防以拉那利尤单抗为一线抗激肽释放酶单抗。共识还涉及儿童、妊娠及哺乳期患者的特殊考量。

要点

  • 诊断流程整合临床表现、C1-INH定量/功能检测及补体C4检测,仅在临床高度怀疑但C1-INH水平/功能正常时行基因测序。
  • 按需治疗使用艾替班特,其为目前中国唯一获批的缓激肽B2受体拮抗剂。
  • 短期预防使用雄激素或新鲜冰冻血浆,用于操作诱因。
  • 长期预防以拉那利尤单抗为一线,其为目前中国可及的首个抗激肽释放酶单抗。
  • 共识强调早期诊断以预防致命性喉水肿,并针对儿童、妊娠及哺乳期患者给出特殊考量。

适用人群与场景

  • 遗传性血管性水肿(HAE-C1-INH)患者,包括儿童、妊娠及哺乳期患者。

诊断标准与关键阈值

  • 诊断流程整合临床表现、C1-INH定量/功能检测及补体C4检测。
  • 基因测序仅用于临床高度怀疑但C1-INH水平/功能正常的病例。

处置流程与药物剂量

  • 按需治疗:使用艾替班特,其为目前中国唯一获批的缓激肽B2受体拮抗剂。
  • 短期预防:使用雄激素或新鲜冰冻血浆,用于操作诱因。
  • 长期预防:拉那利尤单抗为一线,其为目前中国可及的首个抗激肽释放酶单抗。

红旗征与不能漏的情况

  • 致命性喉水肿,共识强调早期诊断以预防。

研究设计与关键结果

  • 制定机构:中国变态反应、耳鼻咽喉、消化、皮肤及急诊医学多学科专家。
  • 方法:协作制定,提供基于证据的HAE-C1-INH管理推荐。

证据类型、等级与局限

  • 证据类型:专家共识。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 共识标准化中国HAE管理,解决诊断能力与治疗可及性的地区差异。
  • 共识强调早期诊断以预防致命性喉水肿,并促进个体化治疗策略。
  • 未来方向包括新兴靶向治疗和疾病严重度预测生物标志物开发。

指南或共识出处

  • 中国遗传性血管性水肿诊断与治疗专家共识(2024版),发表于Int Arch Allergy Immunol。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hereditary angioedema (HAE) is a rare, life-threatening autosomal dominant disorder characterized by recurrent episodes of subcutaneous and submucosal edema. Recent years have witnessed significant advancements in HAE management globally as well as in China, including improved understanding of its pathophysiology and the development of targeted therapies. In China, since the publication of the first national consensus in 2019, accumulating clinical experience and the availability of novel therapeutic agents have created an urgent need to update diagnostic and treatment guidelines to reflect current best practices.

SUMMARY: This updated 2024 consensus was developed through collaboration among multidisciplinary experts in allergy, otorhinolaryngology, gastroenterology, dermatology, and emergency medicine across China. It provides comprehensive, evidence-based recommendations for HAE-C1-INH management. This consensus refined diagnostic algorithms incorporating clinical presentation, quantitative/functional C1-INH assays, and complement C4 testing, with genetic sequencing reserved for cases with strong clinical suspicion but normal C1-INH levels/function. It stratified treatment approaches reflecting China's current therapeutic landscape: (1) on-demand therapy with icatibant, which is the only currently approved bradykinin B2 receptor antagonist in China; (2) short-term prophylaxis using androgens or fresh frozen plasma for procedural triggers; (3) long-term prophylaxis with lanadelumab which is the first-line monoclonal anti-kallikrein antibody available in China. Special considerations for pediatric, pregnant, and breast-feeding patients are also addressed.

KEY MESSAGE: As the first updated consensus since 2019, this guideline standardizes HAE management across China while addressing regional disparities in diagnostic capabilities and treatment accessibility. It emphasizes early diagnosis to prevent life-threatening laryngeal edema and promotes individualized treatment strategies tailored to China's therapeutic landscape. Future directions include emerging targeted therapies and the development of biomarkers for disease severity prediction. Implementation of these recommendations is expected to significantly reduce diagnostic delays, improve patient outcomes, and enhance quality of life for individuals with HAE in China.

来源:Int Arch Allergy Immunol,查看原文。版权归原作者所有。

参考来源

  1. Xu Y, Liu S, Wang X, et al. Expert Consensus on the Diagnosis and Treatment of Hereditary Angioedema in China (2024 Edition). Int Arch Allergy Immunol. 2025. PMID: 40209692. doi:10.1159/000545808

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。